Introduction
• Ticagrelor is widely considered superior to clopidogrel however a pharmacogenetic substudy of PLATO indicated that the majority of this difference is due to genetic nonresponders to clopidogrel.
• We evaluated the outcomes following genotyping for CYP2C19 in a propensity matched ACS cohort treated with either clopidogrel or ticagrelor. 
Methods
• 4,995 WDHB ACS patients were identified by ICD10 coding over a period of 5 years (2012-2016).
• Ticagrelor was subsidised by Pharmac in July 2013.
• Patients were genotyped for CYP2C19 *2, *3 and *17 alleles using either the Nanosphere Verigene analyser or Sequenom Massarray, and treatment tailored accordingly.
• Logistic regression and nearest neighbour propensity matching was employed in a 1:3:3 (genotyped:ticagrelor:clopidogrel) fashion to balance patient characteristics. Groups well balanced by Propensity Matching
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